festations include cortical tubers, cortical dysplasia, subependymal nodules, hydrocephalus, and subependymal giant cell astrocytomas (SEGAs). 1, 24, 32, 37, 40 Subependymal giant cell astrocytomas are benign (WHO Grade I) intraventricular tumors and are almost always associated with TSC. They rarely occur sporadically. The incidence of SEGA is 5%-20% in patients with TSC. 11, 18, 24, 38, 46 These slow-growing tumors arise from the lateral ependymal surface adjacent to the foramen of Monro and project into the lateral ventricle. We have previously reported on a child with TSC and an extraventricular SEGA. 7 These tumors are generally asymptomatic until they obstruct one or both foramina resulting in hydrocephalus, which may include one or both lateral ventricles. Clinical and radiographic monitoring are the mainstays of assessment. 22, 36, 54 Although resection was the only treatment for tumor growth or hydrocephalus, mammalian target of rapamycin (mTOR) inhibitors including everolimus can prevent or reverse SEGA growth. 6, 15, 17, [26] [27] [28] [29] Subependymal giant cell astrocytomas may also hemorrhage, leading to acute neurological deterioration dictating neurosurgical intervention. 39, 47, 51, 52 In this paper we present our experience with the surgical treatment of SEGAs in patients with TSC, one of the largest series of SEGA resections, as well as our current treatment algorithm.
Methods
The medical records and imaging studies of patients diagnosed with TSC who underwent resection of SEGAs between January 1997 and March 2011 were reviewed. A total of 18 patients were identified who underwent surgical excision of a SEGA, with a total of 24 surgeries (including 2 reoperations) performed over 14 years. All patients underwent resection by 1 of 3 neurosurgeons (J.H.W., H.L.W., or D.H.H.). Patients were evaluated according to age at diagnosis and initial treatment. Radiographic imaging was used to identify hydrocephalus preoperatively and postoperatively, as well as the presence of a preoperative or postoperative shunt. We recorded indications for surgery, outcome, length of follow-up, extent of resection, and complications. The Institutional Review Board at New York University Langone Medical Center approved this retrospective analysis.
Patients were offered resection based on multidisciplinary group discussions involving neurosurgeons, neurologists, radiation oncologists, neuroradiologists, and neuropathologists. The decision to proceed with surgery may be complex. While SEGAs are benign, slow-growing lesions, morbidity and death can result from acute hydrocephalus secondary to obstruction of the foramen of Monro. Routine imaging has become the primary modality for SEGA evaluation, with the current emphasis on MRI to avoid excessive radiation exposure from multiple CT scans. Our patients were selected for surgery based on an increase in tumor size, hydrocephalus, or an acute change in the tumor (such as intratumoral hemorrhage). At our institution, microsurgical excision via either an interhemispheric-transcallosal or transcortical-transventricular approach has been the treatment of choice for SEGAs. Recently we have added a purely endoscopic approach for selected cases.
Results
Eighteen patients underwent 24 surgical procedures (including 2 reoperations) for resection of SEGAs (Table  1) . The principal indication for surgery was tumor progression based on routine surveillance MRI in 18 of 24 tumors, ventricular enlargement in 5, and intratumoral hemorrhage in 1 ( Table 2) . No absolute tumor size threshold was used as an indication for surgery. Our cohort comprised 9 males and 9 females. The average age at diagnosis was 16.8 months (range 18-90 months). The average age at the time of surgical intervention was 123.5 months (10.3 years; range 48-300 months). The mean interval between TSC diagnosis and SEGA resection was 106.6 months (8.9 years; Table 1 ). Patients underwent routine annual surveillance MRI once a SEGA was identified. Average follow-up for our resection cases was 52 months (range 12-124 months).
The initial primary resected tumors (22) were on the right side in 9 cases, on the left in 9 cases, and bilateral in 3 cases. The presence of bilateral tumors did not alter our decision to proceed with surgery. Routine early postoperative MRI with and without Gd was used to assess the extent of resection. Postoperative MRI confirmed grosstotal resection (GTR) in 16 of 22 primary tumors ( Table  2) . Gross-total resection was defined as lack of residual tumor by visual inspection intraoperatively and no residual soft tissue mass or enhancement suspicious for tumor on postoperative imaging, as determined by an attending neuroradiologist. Radical subtotal resection (STR), as achieved in 4 primary SEGA resections, was defined as minimal (if any) residual tumor on visual inspection intraoperatively and enhancement of less than 5 mm on postoperative imaging. Two patients (Cases 7 and 15) underwent STR, defined as grossly visible residual tumor on intraoperative inspection or more than 5-mm residual enhancement on postoperative MRI. We do not use intraoperative MRI and routinely use frameless stereotactic navigation. Recurrence of SEGA occurred only in STR cases. These 2 patients underwent a reoperation for GTR of the progressive, residual tumor. No recurrences were identified after primary GTR or radical STR. The extent of preoperative ventriculomegaly had a significant influence on the requirement for CSF diversion before or after SEGA resection (Table 2) . Among patients undergoing the initial resection (n = 18), 5 had no preoperative ventriculomegaly, 4 had mild ventriculomegaly, 4 had moderate ventriculomegaly, and 5 had severe ventriculomegaly. While the Evans's index (ratio of largest diameter of frontal horns to maximal biparietal distance) can be used to provide an objective value for ventriculomegaly, most neurosurgeons and radiologists, including our group, use a subjective measure to quantify the degree of hydrocephalus rather than an absolute numerical threshold.
Preoperatively, 2 patients had ventriculoperitoneal shunts (VPSs) placed prior to tumor resection. One had a VPS placed at an outside institution years prior to our intervention (Case 11) and 1 had an emergency VPS placed for tumor hemorrhage with acute intracranial pressure (ICP) elevation (Case 7). Both of these patients had severe hydrocephalus. Nine of our patients presented with either absent or mild ventriculomegaly. Of these 9 patients, 1 required placement of a postoperative VPS for a cutaneous CSF fistula (Case 12). Thus, 88.9% of our patients (8 of 9) with minimal or no radiographic evidence of ventriculomegaly required no CSF diversion (Table 2) . Eight patients in our study required shunt placement after surgery. Seven of these patients had moderate (n = 4) or severe (n = 3) ventriculomegaly ( Table 2 ). The other patient (Case 12) required a VPS for persistent cutaneous CSF fistula after craniotomy for tumor resection. In summary, 88.9% (8 of 9 of patients) in our series who had moderate to severe preoperative hydrocephalus required postoperative VPS placement ( Table 2 ). Timing of shunt placement ranged from 3 weeks to 1 year postoperatively (mean 3.4 months).
Significant adverse events were observed in 2 (8.3%) of 24 surgeries (Table 2 ). This included 1 contralateral acute epidural hematoma (EDH) requiring craniotomy and 1 patient with a postoperative CSF leak likely due to hydrocephalus. One patient had bilateral caudate edema and another unilateral caudate edema, possibly due to venous hypertension or infarct resulting from thrombosis or venous insufficiency of caudate veins. Bilateral caudate edema resulted in transient somnolence, which resolved within 3 days. No deficits were noted by the family on follow-up, but no preoperative or postoperative neuropsychological evaluation was performed to exclude the possibility of less severe impairment. No deaths occurred and all patients returned to their neurological baseline following surgery. 
Discussion
The natural history of SEGAs in the setting of TSC is generally one of slow growth during the first two decades of life. [10] [11] [12] 19, 24, 35, 37 The most common clinical presentation is elevated ICP due to CSF obstruction at one or both foramina of Monro. Cases of sudden death have been reported.
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Historically, the treatment of choice for tumors that enlarge or cause hydrocephalus has been resection. 3, 5, [11] [12] [13] 23, 24, 30, 33, 36, 44 Multiple patient series have reported on the role of surgery in treating patients with SEGAs ( Table 3 ). The historical incidence of significant, and in some cases, permanent neurological morbidity has been documented (ranging from 5% to 50%). 21, 36, 48 In the current series we have demonstrated that a low rate of surgical complications, excellent tumor control, and minimal or no permanent neurological morbidity can be obtained at an experienced high-volume center. These data may serve as a useful contemporary benchmark for comparisons between medical and surgical therapy. Based on the experience of our group, microsurgical excision remains a valuable treatment option.
Given the benign nature of SEGAs, GTR can be curative for these patients. As shown in our series, GTR or radical STR resulted in no tumor recurrence. Of our 22 tumors, 15 were treated with complete GTR and 5 with radical STR. Two tumors had an STR (Cases 7 and 15) and had progression of residual tumor on follow-up imaging. Both of these patients underwent reoperation for GTR; one (Case 7) underwent surgery 3.5 years later, and the other (Case 15) 4 years later, reflecting the often-indolent growth of these tumors and the need for continued clinical and radiographic follow-up. No recurrences were identified after primary GTR or radical STR. Maximal safe resection is the guiding surgical precept for these benign lesions.
The final decision to operate on SEGAs is based on clinical criteria or radiographic changes in the lesion. Changes in tumor size or the development of hydrocephalus are primary in determining when to treat these lesions surgically. Hydrocephalus is of significant concern; sudden death due to this condition has been reported. 2 We believe that the extent of preoperative ventriculomegaly is the most significant predicting factor for the requirement of CSF diversion. In our cohort, 5 patients initially had no preoperative ventriculomegaly and 4 had mild ventriculomegaly; of these patients "without" hydrocephalus, only 1 required placement of a VPS for persistent cutaneous CSF fistula, likely due to hydrocephalus (11.1%). Alternatively, 4 patients had a moderate degree of preoperative hydrocephalus and 5 had severe hydrocephalus; of these patients with preoperative hydrocephalus, 7 required postoperative VPS placement and 2 had shunts preoperatively. Thus, 11.1% of our patients without preoperative hydrocephalus required CSF diversion and 89.9% of patients with preoperative hydrocephalus required a VPS ( Table 2 ). The extent of preoperative hydrocephalus had a significant bearing on whether CSF diversion was required after SEGA resection. As such, it is our opinion that the majority of patients presenting with moderate to severe ventriculomegaly from a large SEGA causing obstructive hydrocephalus at the foramen of Monro will eventually require CSF diversion; this is important in appropriately counseling families. One explanation for this observation is that a patient with moderate to severe ventriculomegaly already has mechanical obstruction due to the tumor. This obstruction may persist after surgery if there is scarring at the operative site, invariably including the structures in and around the foramen of Monro. After resection, surgical debris, protein, blood products, or hemostatic agents may further impair CSF circulation within the ventricular system, or in the subarachnoid space. Ultimately this combination of intra-and extraventricular obstruction may result in immediate or delayed ventriculomegaly necessitating CSF diversion. This may be observed with other intraventricular tumors (choroid plexus tumors) or skull base tumors (vestibular schwannomas). Our series is among the few that have reported the resection of SEGAs ( Table 3 ). The latest, and second largest series in the past 10 years, by Jiang et al. (2011), 22 reported on 17 SEGAs. Of these 17, 11 (65%) were resected via a transcallosal approach and 6 via a transcortical approach. The series of Jiang et al. revealed an 88% GTR rate and a recurrence rate of 5.9% (1 of 2 patients who underwent STR). Other series including de Ribaupierre et al. 12 and Cuccia et al. 11 reported slightly lower rates of GTR (79% and 80%, respectively), with a predominance of transcortical approaches to these lesions. Their studies revealed a recurrence rate of approximately 20%, all occurring after STR. Our series had a significantly higher number of transcallosal approaches for SEGA resection (16 [72.7%] of 22 tumor resections). This could be due to increased surgeon comfort with this approach. Our series revealed a 90.9% GTR or radical STR rate, the largest among the recent reported SEGA series. Our group had a 9.1% STR rate and a recurrence in both cases of STR. The information from our series, in conjunction with that of the previously reported series, leads us to believe that SEGA recurrence stems from STR of the primary lesion. While these are benign lesions, they do have the tendency to grow over time. Our 2 recurrences occurred at 3.5 and 4 years following the initial resection. This speaks to the importance of long-term follow-up of patients with primary SEGAs as well as those with STR based on postoperative imaging. None of our patients were treated with mTOR inhibition preoperatively or postoperatively. Of specific interest in our series compared with the other reported series is our slightly higher rate of VPS placement (10 [55.6%] of 18 patients ultimately required a VPS), compared with previously reported rates of 6% to 27%.
12,18,22 Our higher rate of VPS placement is mostly likely due to our cohort presenting more frequently with ventriculomegaly and high tumor burden.
Our institutional experience and the volume of SEGA resections is likely the reason for our (and other contemporary series 2 ) low complication rate compared with prior series. Our cases included two significant complications: 1 patient with contralateral acute EDH requiring craniotomy and 1 patient with postoperative CSF leakage from hydrocephalus treated with VPS 3 weeks postoperatively. No deaths occurred and all patients returned to their neurological baseline following surgery, although detailed neuropsychological testing results were not available to rule out subtle impairment. Our low complication rate probably stems from our institutions' increasing experience over time as well as progressive advancements in neurosurgical techniques over the past 10 years. With continued microsurgical, stereotactic, and endoscopic treatment of SEGAs at high-volume centers, we believe that complication rates will continue to decrease.
Operative considerations for the transcallosal and transcortical approaches for other tumor types have been well-documented. [3] [4] [5] 30, 45 Important considerations specific to SEGAs include their location immediately medial to the genu of the internal capsule; excess manipulation may lead to motor deficits of the face or upper extremity. Intraoperative motor-evoked potentials may alert the surgeon to this possibility. Our initial maneuver is to establish the free margins of the tumor anteriorly, medially, and posteriorly, identifying the attachment of the tumor in the caudate nucleus region and protecting the normal surrounding structures with cottonoid patties. The tumor is then truncated, and the portion projecting into the lateral ventricle is removed. The remaining tumor origin is usually heavily calcified, and the use of an ultrasonic aspirator or microscissors may allow cautious debulking of this portion of the tumor, rather than dissection around the tumor interface into the basal ganglia.
Venous anatomy is an additional, important consideration. The thalamostriate vein is usually displaced inferiorly and posteriorly; the base of the tumor may encase it. Care is taken to avoid damage; if a small portion of tumor remains adherent, particularly when calcified, it is left. The caudate vein is usually stretched over the tumor, and occasionally encased; we have attempted to preserve it. The smaller septal vein is usually displaced medially, and is easily separable from the tumor. Identification and preservation of the fornix are also important; we try to identify it early in the dissection, and protect it with a cottonoid patty throughout. Lastly, the choroid plexus is usually displaced superiorly, and may be coagulated and divided with impunity. Microsurgical septostomy at the time of tumor resection has also been performed to potentially simplify shunt procedures if eventually necessary. Although we have performed resection of bilateral SEGAs in a single session, our preference now is to stage these procedures to avoid bilateral forniceal or caudate impairment. External ventricular drains are routinely placed after tumor resection to remove surgical byproducts, tumor debris, and blood.
We have avoided removal of bilateral SEGAs in a single stage given our single case of bilateral caudate edema. Preferentially the larger, more rapidly growing tumor is removed first, with follow-up and surgery on the contralateral SEGA at a later date if needed. The choice of transcortical versus transcallosal approach is based on ventricular size and the presence of prior surgical defect. Large ventricles and/or a prior transfrontal approach (for tuber resection) favor, although do not absolutely dictate, a transcortical route.
Recently we have shown that an endoscopic approach provides a safe and effective minimally invasive option for the treatment of carefully selected tumors.
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Our initial reluctance was based on the broad-based attachment of the tumor to the caudate nucleus, significant calcifications and vascularity of these tumors, as well as a trajectory tangential to, rather than perpendicular to, the tumor. However, when presented with a patient with enlarged ventricles and an expanding but not very large (< 2 cm) SEGA, an endoscopic approach may be appropriate for surgeons possessing adequate experience with similar procedures. With the development of endoscopic techniques and improved instrumentation, the neuroendoscopic approach may come to play a more central role. Endoscopic-assisted craniotomy for SEGA has also been reported. 9 Disadvantages include anatomical limitations, extensive lateral attachment that may preclude GTR, increased time of procedure when compared with craniotomy for larger tumors, and difficulty resecting tumors that may have hemorrhaged, impeding visibility.
Recent understanding of the mTOR signaling pathway in TSC and its regulation via mTOR inhibitors has shown that medical therapy may potentially play a significant role in the management of patients with TSC. 6, 17, 25 Recent studies, including a multicenter, randomized, placebo-controlled Phase-III trial (EXIST-1), have definitively demonstrated significant reduction in the size of TSC-related SEGAs. 16 This has illuminated a potential paradigm shift for the treatment of SEGAs. However, the long-term efficacy for tumor control has not been proven. Complications of mTOR inhibitors include stomatitis and mouth ulcerations among others; in the EXIST-1 trial nearly half of the patients receiving everolimus required a dose reduction due to adverse events. 16 Furthermore, significant questions remain regarding the efficacy, tolerance, and cost of long-term treatment with mTOR inhibitors. 31, 55 In addition, SEGAs tend to regrow once mTOR inhibitors are stopped, potentially necessitating extended treatment. Thus, to date, it is our belief that resection of enlarging tumors or tumors presenting with hydrocephalus will likely continue to remain an important option for treatment. The role for mTOR inhibitors is probably reserved for TSC patients with additional, significant systemic manifestations (renal angiomyolipoma, cardiac rhabdomyoma), as well as in select SEGA cases when the tumor is infiltrative to adjacent structures such as the hypothalamus, genu of internal capsule, and fornix. Another indication for mTOR inhibitors may be as a neoadjuvant therapy prior to surgery to reduce the size of the tumor and possibly increase surgical safety.
If the safety and efficacy of long-term mTOR pathway inhibitors is demonstrated, it is conceivable that this surgical paradigm may be supplanted or augmented by targeted medical therapy. Alternatively, it is possible that a window for treatment exists, perhaps parallel to the clinically observed period of tumor growth during the first decades of life. mTOR inhibitors may also come to play a role in preoperative treatment. A potential strategy could include preoperative treatment with an mTOR inhibitor to decrease tumor size and vascularity, thereby facilitating surgical or stereotactic radiosurgical treatment. 9, 42, 44 Regardless, in the setting of acute hydrocephalus or tumor hemorrhage, it is our opinion that surgical excision will remain the mainstay of treatment and that endoscopic techniques may be the treatment of choice in carefully selected cases. 2, 13, 36, 44 
Conclusions
Based on the experience of our group, microsurgical excision of SEGAs that are symptomatic from hydrocephalus or display significant tumor growth remains an effective and safe treatment option. The results of our series and management framework compare favorably with prior series in terms of morbidity and mortality. This study may serve as a useful benchmark when comparing therapeutic options.
